Primary study objectives:
- To characterise the population and drug utilisation patterns of patients treated with CT-P13 for Crohn’s Disease (CD) or Ulcerative Colitis (UC) in the context of standard of care Remicade
- To explore the long-term safety profile of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Secondary study objective:
- To assess the effectiveness of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Exploratory objectives:
- To evaluate patient-reported outcomes (PRO) including quality of life (QoL), work productivity and healthcare resource use (HRU) in patients treated with CT-P13 for CD or UC